DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET

Company Participants

Rick Pauls - President and CEO

Scott Kellen - CFO

Conference Call Participants

Thomas Flaten - Lake Street Capital

Alex Nowak - Craig-Hallum Capital Group

Dan Hultberg - Oppenheimer

Operator

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K. DiaMedica's SEC filings are available at www.sec.gov and on its website.

Please also note that any comments made on today's call speak only as of today, August 15, 2023, and may no longer be accurate at the time of any replay or transcript re-reading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, we will open the phone lines for questions.

I would now like to introduce your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls, you may begin, sir.

Rick Pauls

Thank you, Paul. Hello, everyone, and welcome to our second quarter conference call. I'm joined this morning by Scott Kellen, our Chief Financial Officer.

Before we begin this morning, I want to take a moment to welcome Dr. Richard Kuntz to our Board of Directors. Dr. Kuntz recently retired from Medtronic, where he was the Chief Medical Officer, Chief Scientific Officer and a member of the Executive Committee. Prior to that, he served as a Senior Vice President and President, Neuromodulation at Medtronic. Before Medtronic, he was the Founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston. He also served as an Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Clinical Biometrics and as an Interventional Cardiologist in the division of cardiovascular diseases at the Brigham and Women's Hospital in Boston. He also served as an adviser to multiple national and regional committees in the National Academy of Medicine and National Institutes of Health. Dr. Kuntz has directed numerous multi-center clinical trials and has authored over 200 original publications. We are grateful to have Rick join our Board. His experience complements and broadens the knowledge and skill set of our Board.